Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Scheffler

Showing results (171-180 of 207) with videos related to

Pageof 21
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 10, 2023
MET Fusions in NSCLC: Clinicopathologic Features and Response to MET InhibitionRichard Riedel, Jana Fassunke, Andreas H Scheel, et al.
Oncotarget|April 15, 2015
ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variabilityMatthias Scheffler, Anne Schultheis, Cristina Teixido, et al.
Lung Cancer (Amsterdam, Netherlands)|May 4, 2020
Co-occurrence of targetable mutations in Non-small cell lung cancer (NSCLC) patients harboring MAP2K1 mutationsMatthias Scheffler, Alessandra Holzem, Anna Kron, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 5, 2020
Treatment Monitoring of Immunotherapy and Targeted Therapy Using <sup>18</sup>F-FET PET in Patients with Melanoma and Lung Cancer Brain Metastases: Initial ExperiencesNorbert Galldiks, Diana S Y Abdulla, Matthias Scheffler, et al.
Advances in Therapy|January 18, 2023
An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion MutationsChristos Chouaid, Lise Bosquet, Nicolas Girard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 19, 2025
Molecular and clinical characteristics of patients with non-small cell lung cancer (NSCLC) harboring KRAS G12V mutationsFelix John, Lea Ruge, Malte Verheyen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2016
Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue SarcomaPriya Chudasama, Marcus Renner, Melanie Straub, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2011
Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomographyThomas Zander, Matthias Scheffler, Lucia Nogova, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 23, 2015
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF CohortOliver Gautschi, Julie Milia, Bastien Cabarrou, et al.
The Lancet Regional Health. Europe|November 30, 2023
Evaluation of the effectiveness of a nationwide precision medicine program for patients with advanced non-small cell lung cancer in Germany: a historical cohort analysisAnika Kästner, Anna Kron, Neeltje van den Berg, et al.
Pageof 21

Showing results (171-180 of 207) with videos related to

Sort By:
Pageof 21
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 10, 2023
MET Fusions in NSCLC: Clinicopathologic Features and Response to MET InhibitionRichard Riedel, Jana Fassunke, Andreas H Scheel, et al.
Oncotarget|April 15, 2015
ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variabilityMatthias Scheffler, Anne Schultheis, Cristina Teixido, et al.
Lung Cancer (Amsterdam, Netherlands)|May 4, 2020
Co-occurrence of targetable mutations in Non-small cell lung cancer (NSCLC) patients harboring MAP2K1 mutationsMatthias Scheffler, Alessandra Holzem, Anna Kron, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 5, 2020
Treatment Monitoring of Immunotherapy and Targeted Therapy Using <sup>18</sup>F-FET PET in Patients with Melanoma and Lung Cancer Brain Metastases: Initial ExperiencesNorbert Galldiks, Diana S Y Abdulla, Matthias Scheffler, et al.
Advances in Therapy|January 18, 2023
An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion MutationsChristos Chouaid, Lise Bosquet, Nicolas Girard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 19, 2025
Molecular and clinical characteristics of patients with non-small cell lung cancer (NSCLC) harboring KRAS G12V mutationsFelix John, Lea Ruge, Malte Verheyen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2016
Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue SarcomaPriya Chudasama, Marcus Renner, Melanie Straub, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2011
Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomographyThomas Zander, Matthias Scheffler, Lucia Nogova, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 23, 2015
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF CohortOliver Gautschi, Julie Milia, Bastien Cabarrou, et al.
The Lancet Regional Health. Europe|November 30, 2023
Evaluation of the effectiveness of a nationwide precision medicine program for patients with advanced non-small cell lung cancer in Germany: a historical cohort analysisAnika Kästner, Anna Kron, Neeltje van den Berg, et al.
Pageof 21